Medicine Matters is a pan-specialty podcast for doctors, that discusses the most exciting, controversial, and practice-changing topics across medical practice as a whole. In our episodes, we’ll be talking to leading clinical experts, to researchers and funding institutes, and to industry partners about the well-known and perhaps the lesser-known issues affecting doctors in their clinics. We’ll be looking at everything from new drug approvals to social issues affecting medicine, and we’ll be challenging some of the status quo along the way.
All content for Medicine Matters: The Springer Medicine Podcast is the property of Editorial office Springer Medicine and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Medicine Matters is a pan-specialty podcast for doctors, that discusses the most exciting, controversial, and practice-changing topics across medical practice as a whole. In our episodes, we’ll be talking to leading clinical experts, to researchers and funding institutes, and to industry partners about the well-known and perhaps the lesser-known issues affecting doctors in their clinics. We’ll be looking at everything from new drug approvals to social issues affecting medicine, and we’ll be challenging some of the status quo along the way.
We talk with Prof. Daniel Drucker about the early work on GLP-1 medicines for the treatment of diabetes, how they are now impacting the lives of people living with obesity, and their potential use for many other indications.
We talk to Dr. Cristina Saura about the concerns around breastfeeding after a breast cancer diagnosis, and why the POSITIVE results are such good news.
Prof. Vlad Ratziu discusses the updated subclassification and nomenclature for steatotic liver disease, the therapeutic advance of resmetirom, and the future for MASLD and MASH.
Dr. Eduard Shantsila discusses rehabilitation approaches for complex patients with heart disease and comorbid frailty, including those with cognitive vulnerability.
Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.
Prof. Marion Subklewe explores the interplay between the gut microbiota and the efficacy and safety of CAR T-cell therapy in people with hematologic malignancies.
Prof. Susanne Wegener discusses her team’s work to develop deep learning models that outperform neurologists in predicting patients’ clinical outcomes after stroke.
Professor Andrew Beggs discusses best practice in the use of next-generational sequencing within thyroid and non-small cell lung cancers.
This content is intended only for healthcare providers and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company
Prof. Malin Parmar explains why stem cell therapy is such a good option for patients with Parkinson’s disease and how its safety is being tested in the STEM-PD trial.
Professors Morris Brown and Bryan Williams join Jane Godsland to explore the theories behind resistant hypertension, and the latest treatment approaches.
We speak to Dr. Elena Castro about the latest data on PARP inhibitors in prostate cancer as presented at this year's ASCO Genitourinary Cancers Symposium.
Medicine Matters is a pan-specialty podcast for doctors, that discusses the most exciting, controversial, and practice-changing topics across medical practice as a whole. In our episodes, we’ll be talking to leading clinical experts, to researchers and funding institutes, and to industry partners about the well-known and perhaps the lesser-known issues affecting doctors in their clinics. We’ll be looking at everything from new drug approvals to social issues affecting medicine, and we’ll be challenging some of the status quo along the way.
